MedTrace Logo

Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation

NCT03570047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73989

Last updated 2019-11-04

Study results available
· View outcomes & findings →

Summary

An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of thromboembolism and it had long been the only oral anticoagulant until the first non-vitamin K antagonist oral anticoagulants (NOACs). However, its safety and effectiveness remains unknown in real-world clinical practice in Japan

Conditions

  • Non-valvular Atrial Fibrillation

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-08
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03570047 on ClinicalTrials.gov